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Donor dendritic cells after liver and heart 
allotransplantation under short-term 
immunosuppression 
SIR,-Donor (LEW) dendritic cell dissemination into recipient 
(BN) tissues was assessed in rats 16,30, and 70 days after orthotopic 
liver transplantation (n = 3) and 30 days after intra-abdominal heart 
transplantation (n = 4), according to previously described surgical 
techniques.' Intramuscular FK 506 (I mg/kg) was given to liver 
recipients daily for 7 days, but continued for 14 days in heart 
recipients because of the greater vulnerability to rejection of cardiac 
compared with hepatic grafts.' The same doses were then continued 
twice a week. Immunolabelling with a mouse monoclonal antibody, 
L-21-6, which recognises the invariant chain of LEW and most 
other rat strains, but not BN class II MHC antigen,' allowed the 
distinction of donor from recipient cells. 
L-21-6 + (donor) dendritic-shaped cells were detected in 
lymphoid tissues of the non-rejecting LEW -BN liver recipients at 
16, 30, and 70 days. These cells were restricted to the periarterial 
lymphatic sheaths of the spleen, and the paracortex of mesenteric, 
cervical, and intrathoracic lymph nodes, but diminished with time 
(figure). Occasional cells were also detected in the thymic medulla 
and non-lymphoid organs, such as the heart and skin, but not the 
brain. Liver allografts showed mild mononuclear infiltration with 
increased numbers of mast cells, but there was no evidence of 
parenchymal damage or obliterative arteriopathy. Residual donor 
(L-21-6 + ) dendritic cells were present in portal tracts and beneath 
the tenninal hepatic venules at all time points examined. 
Despite a longer period of daily FK 506 treatment, heart 
allografts had obliterative arteriopathy, indicating low-grade graft 
rejection. As in the liver transplants, the mild cellular infiltrate in 
heart allografts contained increased numbers of mast cells. An 
estimated one quarter of the normal quantity of dendritic cells in the 
cardiac graft interstitium and around blood vessels was identified as 
the persistent L-21-6 + (donor) phenotype. Unlike liver recipients, 
heart recipients had only rare donor dendritic cells in their spleen 
and lymph nodes, none in thymus, and none in non-lymphoid 
tissues, skin, lung, native heart, adrenal glands, kidneys, liver, 
intestines, and brain. 
When liver transplantation was done across the immunologically 
more difficult ACI-BN strain barrier (n = 3), donor cell 
dissemination to eXtrahepatic tissues at 30 days resembled that after 
LEW-BN cardiac allotransplantation. Donor dendritic cells 
persisted irregularly in the liver grafts but were sparse or 
undetectable at extrahepatic sites. 
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Donor dendritic cell repopulation in 
recipients after rat-to-mouse bone-marrow 
transplantation 
SIR,-Bone-marrow-derived dendritic cells are powerful 
antigen-presenting cells, which are IOO-£in1es more effective than 
macrophages in activating T lymphocytes in mixed-lymphocyte 
culture' and in intact animals.' These cells are pivotal in the 
generation of the T-cell repertoire, including provision of the 
appropriate ligand for negative selection of potentially autoreactivc 
T lymphocytes.' We now describe the tissue distribution of donor 
dendritic accessory cells in fully xenogenic (F344 rat ..... B 10 mouse) 
radiation bone-marrow chimeras that were pennanentiy tolerant to 
donor-specific xenoantigens, yet fully reactive to third-party mouse 
and rat lymphoid cells.·.5 
Laboratory animals were typed for chimerism by flow cytometry, 
and 3 per group were killed for a complete tissue survey at 1,2,3,4, 
6, and 8 weeks and at 8 months after reconstitution. 
Immunohistochemical staining for rat -derived dendritic cells (class 
II bright) was with the monoclonal antibody L-21-6 directed at the 
invariant chain of the rat class II molecule without cross-reactivity 
in mouse cells (provided by Dr Yuichi lwaki, University of 
Pinsburgh). 
Donor-recipient histological changes one month after rat liver allotransplantation under FK 506 immunosuppression. 
Periarterial lymphatic sheath of spleen (left); thymic medulla (right) . Immunoperoxidasestain with L-21 -6 monoclonal antibody and haematoxylin 
counter stain (~ 300- ~ 500) . 
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Mouse thymus (top) and skin (bottom) six months after 
rat-to-mouse bone-marrow transplantation. 
Top, staining by anti-MHC class" (L-21-6). Rust-coloured rat-
derived cells are seen in both thymic cortex (C) and medulla (M) 
(x 300). 
Bottom, L-21-6-positive-dendritic cells are shown in skin from the 
same animal ( x 300). 
In the first 2-3 weeks after reconstitution, the structure of the 
class-II -positive rat cells migrating into the tissue of the mice 
appeared more rounded than stellate and were thought to be an 
irrunature, less differentiated form of dendritic cell. By the end of 
one month and invariably thereafter, the rat dendritic cells were 
fmUld in all of the mouse tissues examined: thymic cortex and 
medulla (figure, top), spleen, other lymphoid structures, liver, fat, 
peripheral nerve roots, brain (cerebellwn, cerebrum), trachea, 
oesophagus, pancreas, lungs, bronchi, heart, and skin (figure, 
bonom). Their morphology, cell density, and distribution in the 
chimeras resembled that of normal rat tissues examined as controls. 
The extent as well as the normal panem of "homing" of the rat 
bone-marrow-derived dendritic cells in a xenogeneic mouse 
environment, suggests the presence of a highly conserved rcceptor-
ligand mechanism. We are currently investigating the possible role 
of these ubiquitous cells in the induction and maintenance of 
specific transplanration tolerance across both allogeneic and 
xenogeneic histocompatibility barriers. 
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Antimyeloperoxidase antibodies and adverse 
reactions to clozapine 
SIR,-The use of c10zapine has been limited by idiosyncratic 
drug reactions, especially agranulocytosis.' Many such reactions 
seem to be initiated by reactive metabolites rather than by the parent 
drug,> and since these merabolites usually have short biological 
half-lives and the rarget organ in agranulocytosis is the bone 
marrow, the mechanism might involve formation of reactive 
metabolites by bone-marrow cells, Myeloperoxidase seems to be 
the major system in leucocyres that can oxidise drugs to reactive 
merabolites,' When mature neutrophils, monocytes, and some 
neutrophil precursors are activated, they release myeloperoxidase 
and generate hydrogen peroxide. This combination, in tum, oxidise 
chloride ion to hypochlorous acid. Many drugs that are associated 
with a high incidence of agranulocytosis are merabolised to reactive 
intermediates by this system.' It has been reported that c10zapine is 
merabolised by myeloperoxidase to a reactive free radical; and we 
have evidence that it is merabolised to a reactive nitreniurn ion.' 
Antibodies against myeloperoxidase have been described in 
various types of vasculitis' and hydralazine-induced lupus.' We 
therefore sought evidence of these antibodies in patients with 
c1ozapine-induced adverse drug reactions. We obtained serum 
samples from 6 patients from the Netherlands with c1ozapine-
induced agranulocytosis while they were still neutropenic. We also 
investigated a patient at Sunny brook Health Science Centre. 
A 53-year-old woman presented with an I8-year history of 
chronic paranoid schizophrenia. Her symptoms had been refractory 
to numerous neuroleptic trials. In the year before admission, facial 
movements compatible with rardive dyskinesia had arisen. Due to 
the unremitting psychotic symptoms and signs of tardive 
dyskinesia, a trial of clozapine was proposed. Perphenazine and 
flupenthixol decanoate were rapered and discontinued. Clozapine 
was given, srarting at 25 mg daily (day I, figure), and increased by 
25 mgdaily. 
On day IS fever (38'5°), diaphoresis, myalgia, arthralgia, and 
urticarial plaques on elbows, knees, and bunocks developed. 
Clozapine was stopped, and diphenhydramine was given for 
